A new study found that the majority of women living with HIV would endorse a monthly long acting injectable (LAI) antiretroviral therapy over current daily pills. LAI HIV therapy has completed Phase III trials and is awaiting Food and Drug Administration approval. Over half of the women would choose LAI HIV therapy over daily pills for convenience, privacy, and perceived effectiveness. This study is the first to exclusively explore women’s interest in LAI HIV therapy.
- Vermont’s BIPOC drivers are most likely to have a run-in with police, study shows
- Many parents say teens with anxiety, depression may benefit from peer confidants at school
- Where COVID-19 hit hardest, sudden deaths outside the hospital increased
- Scientists shed light on how and why some people report “hearing the dead”
- Changing diets — not less physical activity — may best explain childhood obesity crisis